RE:RE:BMS to buy Turning Point Therapeutics for 4.1B$US4.1B$US for such a small market of NSCLC! Repotrectinib is one of several molecules designed to treat cancers driven by ROS1-fusion mutations. Patients with ROS1 rearrangements, which are found in 1% to 2% of people with non-small cell lung cancer (NSCLC), are already served by Pfizer’s Xalkori and Roche’s Rozlytrek. Yet, Turning Point has spied an opportunity to muscle into the field and persuaded investors it has a shot at doing so.
Bristol Myers Squibb has nabbed Turning Point Therapeutics in a $4.1 billion buyout deal, just weeks after the biotech posted an upbeat round of positive human data for its lead drug, repotrectinib.
The buyout — at $76 a share — gives Bristol Myers a rival to Pfizer’s Xalkori and Roche’s Rozlytrek in ROS1-positive non-small cell lung cancer.